Shingles News and Research

RSS

Shingles (herpes zoster) is an outbreak of rash or blisters on the skin that is caused by the same virus that causes chickenpox — the varicella-zoster virus. The first sign of shingles is often burning or tingling pain, or sometimes numbness or itch, in one particular location on only one side of the body.

Tamir's compounds perform better than Ganciclovir for Cytomegalovirus disease: Study

Tamir Biotechnology, Inc. announced today that scientists supported by the National Institute of Allergy and Infectious Diseases (NIAID) reported test results confirming two of our lead compounds outperformed market leader Roche's drug Ganciclovir in cell culture and plaque reduction assay (the gold standard) for Cytomegalovirus (CMV) disease. Additionally, antiviral activity was also apparent against other human herpesviruses, namely, HSV-1 (cold sores), HSV-2 (genital herpes), and Varicella-Zoster Virus (VZV) (chicken-pox and shingles).

29 Sep 2010

Many adults skip vaccines because of costs

The New York Times' Patient Money column examines the importance of vaccines for adults.

28 Sep 2010

Walgreens pharmacists in California offer immunizations that protect against pertussis

With the state of California on pace for the worst epidemic of pertussis, or whooping cough, in nearly five decades, officials from the Centers for Disease Control and Prevention as well as the California Department of Public Health continue to strongly encourage vaccination to help increase immunity and stop the spread of the disease for all Californians.

18 Sep 2010

PLX-PAD therapy improves quality of life in CLI patients

Pluristem Therapeutics Inc. today reported that data from clinical trials show the Company's placenta-derived cell therapy, PLX-PAD, is safe and improves quality of life as well as other efficacy measurements in patients with Critical Limb Ischemia (CLI), the end-stage of Peripheral Artery Disease (PAD).

15 Sep 2010

CTTC's Calmare therapy effective against pain associated with chemotherapy-induced peripheral neuropathy

Competitive Technologies, Inc. announced today the publication of the detailed results from a study that shows the successful treatment of patients suffering from pain associated with chemotherapy-induced peripheral neuropathy (CIPN) using CTTC's Calmare® Pain Therapy Treatment

9 Sep 2010

Researchers complete INX-189 clinical trials for Hepatitis C virus

The first clinical trials on a new investigational drug being developed to treat infections caused by Hepatitis C virus have been successfully completed.

3 Sep 2010

Inhibitex completes INX-189 Phase1a trial for HCV

Inhibitex, Inc., announced today that it has successfully completed a Phase1a, first-in-man, single ascending dose trial of INX-189, its nucleotide polymerase inhibitor in development for the treatment of chronic hepatitis C (HCV) infections. In this trial, 42 healthy volunteers received either a single oral dose of INX-189, ranging from 3 mg to 100 mg, or placebo. The Company plans to present detailed results from this trial during a future scientific meeting.

2 Sep 2010

Wound Management Technologies' CellerateRX introduced at DFWG congress in South Africa

Wound Management Technologies, Inc. announced today that its new international distributor, Spiramed (Pty) Ltd, exhibited its advanced wound care collagen product, CellerateRX® last weekend at the DFWG (Diabetic Foot Working Group) congress in Cape Town and has already planned exhibitions at two additional upcoming conferences. This second meeting of the DFWG congress was attended by over 120 diabetic foot specialists.

18 Aug 2010

Pharmacists in all states authorized to administer influenza vaccines

The American Pharmacists Association (APhA) is encouraging consumers to get immunized against influenza and to consider their local pharmacy as the site to receive their vaccine. Pharmacists in all 50 states including the District of Columbia are authorized to administer influenza vaccines and, as of June 30, 2010, more than 120,000 U.S. pharmacists have been trained to administer immunizations.

18 Aug 2010

Wound Management Technologies introduces CellerateRX wound care collagen product in South Africa

Wound Management Technologies, Inc. is pleased to announce the sales expansion of its advanced wound care collagen product, CellerateRX, into South Africa. With EWA Government Systems and Spiramed (Pty) Ltd., the Company has obtained the registration of the product in the region and has also obtained the necessary NAPPI codes, which are a pre-requisite for any billable health product in South Africa. In addition, CellerateRX® is registered with various South African insurance companies and is an authorized product for reimbursement.

12 Aug 2010

Inhibitex reports net loss of $5.6 million for second-quarter 2010

Inhibitex, Inc. today announced its financial results for the second quarter ended June 30, 2010.

10 Aug 2010

Pluristem's PLacental eXpanded cell therapy effective against neuropathic and inflammatory nerve pain

Pluristem Therapeutics Inc. today announced the results of two separate pre-clinical studies in animal models which demonstrated that its PLacental eXpanded (PLX) cell therapy may be an effective treatment for both neuropathic and inflammatory nerve pain. These animal studies were conducted in collaboration with the Berlin-Brandenburg Center for Regenerative Therapies (BCRT) and the Department of Anesthesiology and Operative Intensive Care Medicine, both at the Charité-Universitätsmedizin of Berlin, Germany.

10 Aug 2010

NeurogesX net loss for second-quarter 2010 increases to $10.2 million

NeurogesX, Inc., a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today reported results for its second quarter ended June 30, 2010.

7 Aug 2010

Summer Academy Meeting highlights benefits of HPV, Herpes Zoster vaccines

Vaccines have a long history of successfully preventing disease and, in effect, improving the lives of countless Americans. Now, two serious diseases - human papillomavirus (HPV) and herpes zoster - could become a thing of the past as people better understand the safety and efficacy of vaccines to prevent these serious viral infections in specific populations.

6 Aug 2010

MRCC deploys CTT's Calmare Pain Therapy Treatment medical device

Competitive Technologies, Inc. announced that McKinney Regional Cancer Care Center, a private physician oncology practice based in McKinney, TX, is the first cancer center in Texas treating with CTT's Calmare Pain Therapy Treatment medical device. Patients suffering from pain related to cancer are being treated under the direction of medical oncologist Dennis Birenbaum, M.D.

3 Aug 2010

Merck reports strong bottom-line performance in second quarter

Merck & Co., Inc. today announced financial results for the second quarter of 2010. The company reported non-GAAP (generally accepted accounting principles) earnings per share (EPS) for the second quarter of $0.86, which excludes purchase accounting adjustments, merger-related expenses, restructuring costs and the gain on AstraZeneca's asset option exercise. Second-quarter GAAP EPS was $0.24.

2 Aug 2010

Commonwealth Pain Specialists offers treatment with CTT's Calmare Pain Therapy device

Competitive Technologies, Inc. announced today that Commonwealth Pain Specialists, the premier pain management center in Richmond and Central Virginia, is treating patients suffering from chronic, intense neuropathic pain using CTT's Calmare® Pain Therapy medical device.

31 Jul 2010

Independent DSMB recommends Inhibitex to complete FV-100 Phase II clinical trial for shingles

Inhibitex, Inc. today announced that the independent data safety monitoring board (DSMB) responsible for reviewing safety data from the Company's ongoing Phase II clinical trial of FV-100 met, as scheduled, after the Company had provided it with complete 30-day follow-up safety data on the third quartile (75%) of the patients that the Company plans to enroll in the trial. Based upon its review, the DSMB recommended that the trial continue to completion without modification.

23 Jul 2010

Competitive Technologies anticipates $1M revenue from sales of Calmare Pain Therapy Treatment

Competitive Technologies, Inc. today announced it expects revenue from sales of its Calmare® Pain Therapy Treatment for the fourth quarter of fiscal 2010 to be about $1 million, nearly double that of the prior quarter. The Company expects significant additional growth in Calmare medical device sales in upcoming quarters resulting from the growing U.S. sales force of over 35 sales representatives.

19 Jul 2010

Wound Care Innovations signs distribution agreement with KOMED for CellerateRx

Wound Management Technologies, Inc. announced an important milestone in its planned growth strategy. Its wholly owned subsidiary Wound Care Innovations signed a distribution agreement with KOMED, LLC of Georgia for direct response advertising on television and niche online marketing of CellerateRx® in the United States.

1 Jul 2010